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Studies of the properties of soluble oligomer species of amyloidogenic proteins, derived
from different proteins with little sequence homology, have indicated that they share a
common structure and may share similar pathogenic mechanisms. Amyloid β, tau protein,
as well as amyloid precursor protein normally associated with Alzheimer’s disease and
Parkinson’s disease were found in lesions and plaques of multiple sclerosis patients. The
objective of the study is to investigate whether brain and cerebrospinal fluid (CSF) samples
derived from multiple sclerosis patients demonstrate the presence of soluble oligomers
normally associated with protein-misfolding diseases such as Alzheimer’s disease.We have
used anti-oligomer monoclonal antibodies to immunodetect soluble oligomers in CSF and
brain tissues derived from multiple sclerosis patients. In this report, we describe the pres-
ence of soluble oligomers in the brain tissue and cerebral spinal fluid of multiple sclerosis
patients detected with our monoclonal anti-oligomer antibodies with Western blot and
Sandwich enzyme-linked immunosorbent assay (sELISA). These results might suggest
that protein aggregation plays a role in multiple sclerosis pathogenesis although further
and more refined studies are needed to confirm the role of soluble aggregates in multiple
sclerosis.
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Multiple sclerosis, the prototypical human inflammatory demyeli-
nating disease of the central nervous system (CNS), represents a
significant health burden, affecting the quality of life of many
people.
Despite the important role played by T cells in the pathogenesis
of MS, it is now well recognized that B cells and humoral immune
responses form an important component of the mechanisms
underlying disease pathogenesis (1). Oligoclonal immunoglob-
ulins of IgG and IgM isotype are consistently recognized in all
forms of MS and their status informs prognosis in MS patients
(2) and are used as a diagnostic tool for the disease. These
oligoclonal immunoglobulins together with memory B cells and
plasma cells that led to their secretion were consistently isolated
from patients with MS. Surprisingly, these memory B cells and
plasma cells and the secreted immunoglobulins were demon-
strated even at onset of clinical symptoms of MS, suggesting
prolonged and continuous antigen stimulation likely by auto-
antigens (3). The specific subtype of B cell isolated in patients
with MS is recognized as part of the so-called T-independent
B-cell immune response, and sequencing the immunoglobulins
CDR regions derived from these B cells demonstrated abnormal
pattern of somatic hypermutation (4). T-independent B-cell acti-
vation is part of the humoral immune response to pathogens;
consequently, antigen alone, or antigen plus signals provided by
cells other than T cells can provide all necessary signals in order
to induce a B-cell response (5). Bachmann and colleagues demon-
strated the importance of T-independent B-cell responses through
stimulating antigen-specific B cells to proliferate and secrete IgM
in vivo in T-cell-deficient mice (6). We have also shown previously
that immunization with amyloid component of native prions leads
to T-independent B-cell immune response with chronic secretion
of abnormally hyper mutated IgM (Tayebi and David, Personal
communication). In prion disease, failure of classical immune pro-
tection to “neutralize” auto-antigens suggests a highly aggregated
state of these proteins and their ability to resist low pH in the
endosomal environment renders them unable to properly process
such proteins in an MHC class II-restricted pathway that involves
T-cell help (7). The failure to process these auto-antigens through
classical pathways has perhaps led the immune system to use“alter-
native” pathways, namely the T-independent B-cell responses as is
well recognized with so-called thymus-independent (TI)-1 and 2
antigens (6).
Amyloid deposits are described in many CNS disorders. In
Alzheimer’s disease (AD), the commonest form of human amy-
loidosis, amyloid deposits are displayed as extra-cellular senile
plaques in the gray matter and cortex. Amyloid plaque formation
is also seen in gray matter of brains that are prion diseased.
In MS, amyloid precursor protein (APP), abundantly found in
amyloid plaques associated with AD pathogenesis (8), was asso-
ciated with lesions and plaques (9). Furthermore, patients with
primary progressive MS displayed increase of amyloid β (Aβ) and
tau protein levels in their CSF.
In this study, we investigated whether soluble oligomers, com-
mon to most amyloids, may be present in CSF and brain tissues
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FIGURE 1 | Immunodetection of Aβ and tau oligomers in brains of
Alzheimer’s disease patients with the PRIOC monoclonal antibodies.
Brain sections (7µm thickness) derived from Alzheimer’s disease patients
(patient case number 51486; 60649; 60980) and from a control brain derived
from a patient with cancer (patient case number 58695) were stained with
PRIOC, 4G8 (stains Aβ plaques), or AT8 mAb (stains phosphorylated tau). The
control 58695 case displayed no staining for oligomers, Aβ plaques, and
pathological tau. The 51486 case showed a diffuse pattern of medium-sized
aggregates with PRIOC mAb and large plaques with 4G8. Confocal studies
displayed co-staining of both the plaques and the aggregates. Cases 60649
and 60980 displayed extensive intracellular staining (green fluorescence) and
smaller plaques.
of MS patients to lay the ground for further studies characteriz-
ing the toxicity of soluble oligomeric species and its involvement
in MS pathogenesis. We hypothesized that oligoclonal antibod-
ies consistently found in MS patients (10) are stimulated by
toxic soluble oligomers and are secreted through the so-called
T-cell-independent B-cell immune response.
We have recently demonstrated that monoclonal antibodies
(mAbs) called PRIOC mAbs raised against prion oligomers were
also able to immunodetect synthetic Aβ and α-synuclein solu-
ble oligomers (11). The PRIOC mAbs were produced following
subcutaneous immunization of FVB/N Prn-p0/0 with Dynabead-
adsorbed prions. PrPC or PrPSc-positive hybridomas were gener-
ated for the production of mAbs specific for soluble oligomers.
These PRIOC mAbs were shown to bind only the oligomeric
species but failed to bind to both the monomers and the fibril
counterparts. Similarly, our PRIOC mAbs were also able to bind
synthetic oligomeric species of tau and islet amyloid polypeptide
(IAPP) associated with tauopathies and type 2 diabetes, respec-
tively, but not with their monomeric and fibrils counterparts
(data not shown). Kayed and colleagues (12) have also shown that
polyclonal sera raised against Aβ peptide oligomers also detected
α-synuclein, IAPP, polyglutamine, lysozyme, human insulin, and
prion oligomers. Taken together, these results argue that a confor-
mational epitope is detected by PRIOCs, independently of their
primary sequences. We then tested the ability of the PRIOC mAbs
to detect Aβ soluble oligomers in AD patients by immunohisto-
chemistry and immunofluorescence as previously described (11,
13). Here, we show that PRIOC antibody staining displayed a
diffuse pattern of medium-sized intracellular aggregates, consis-
tent with staining of soluble oligomers (Figure 1). In contrast,
the Aβ-4G8 (14) and the AT8-tau (15) specific antibody bound
large extra-cellular Aβ plaques and intracellular tau aggregates,
respectively (Figure 1).
These antibodies were used to detect soluble oligomers in brain
homogenates and CSF from patient with MS; surprisingly, the
anti-oligomer mAbs were able to specifically recognize oligomers
by Western blot in four patients with MS but not in controls. Our
anti-oligomer mAbs detected synthetic oligomers produced from
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Table 1 | Summary details of MS cases used in this preliminary study.
Case number Type Died age
(years)
Sex Brain weight
(grams)
CSF pH Cause of
death
Death-tissue preservation
interval (hours)
Tissue
provided
Preservation
protocol
MS050* SPMS 72 F 1175 – BP; MS 8 B; SC P; FF; SF
MS058* SPMS 51 F 1000 – MS 15 B; SC P; FF; SF
MS062* SPMS 49 F 935 – RI 10 B; SC P; FF; SF
MS074* SPMS 64 F 889 7.42 AP 7 B; SC; CSF P; FF; SF
MS076* SPMS 49 F 1139 6.24 CRF; HD 31 B; SC; CSF P; FF; SF
MS079* SPMS 49 F 969 6.94 BP; MS 7 B; SC; CSF P; FF; SF
MS094* PPMS 42 F 1229 – BP; MS 11 B; CSF P; FF; SF
MS097* SPMS 55 M 1190 – BP; MS 31 B; SC; CSF P; FF; SF
MS122* SPMS 44 M 1400 6.19 BP 16 B; SC; CSF P; FF; SF
MS166* SPMS 52 F 891 – BP; MS 7 B P; FF; SF
MS200* SPMS 44 F 1205 6.9 UTI; S; MS 20 B; SC P; FF; SF
MS229* SPMS 53 M 1219 7.2 BP; MS 13 B; SC P; FF; SF
MS302* SPMS 59 M 995 6.5 S; UTI 8 B; SC P; FF; SF
MS311* SPMS 45 F 973 – P 22 B; SC P; FF; SF
MS313* PPMS 66 M 1266 7.32 PU; MS 16 B; SC P; FF; SF
MS060* SPMS 55 M 1360 6.58 MS 16 CSF SF
MS082* SPMS 49 F 1057 – AP 9 CSF SF
MS154* SPMS 34 F 1244 7.5 P 12 CSF SF
MS104* SPMS 53 M 1100 6.55 MS 12 CSF P; FF; SF
MS106* NS 39 F 1010 6.48 BP 18 CSF SF
CO41* control 54 M 1829 7.5 LC 20 B; SC; CSF P; FF; SF
PD020* PD 75 M 1351 – – 12 B; SC; CSF P; FF; SF
MD01 PPMS – – – – – – CSF; Blood SF
MD02 SPMS – – – – – – CSF; Blood SF
58695 C 63 M – – Cancer – B P; FF
51486 AD 79 M – – AD – B P; FF
60649 AD 65 M – – AD – B P; FF
60980 AD – M – – AD – B P; FF
PPMS, primary progressive; SPMS, secondary progressive; PD; Parkinson’s disease; ND, not done; NS, not specified; BP, bronchopneumonia; AP, aspiration pneumo-
nia; P, pneumonia; LC, lung cancer; RI, respiratory infection; CRF, chronic renal failure; HD, heart disease; UTI, urinary tract infection; S, septicemia; PU, peptic ulcer;
NK, not known; B, brain; SC, spinal corf; CSF, cerebrospinal fluid; P, paraffin; FF, fixed-frozen; SP, snap-frozen. *Provided by The UK Multiple Sclerosis Tissue Bank.
monomeric recombinant PrP (rPrP), Aβ peptide, and α-synuclein
(11). We showed that only the oligomeric species derived from
monomers were immunodetected by PRIOC mAbs that failed to
bind to both the monomers and the fibrils (11).
In this study, we investigated whether soluble oligomers, com-
mon to most amyloids, may be present in CSF and brain tissues
of MS patients to lay the ground for further studies characterizing
the toxicity of soluble oligomeric species and its involvement in
MS pathogenesis. Fresh frozen MS and normal control brain sam-
ples obtained at autopsy under The UK Multiple Sclerosis Tissue
Bank-approved protocol (Table 1) were used in this study. Samples
derived from cerebral hemispheres were harvested then frozen at
−80° C until further use. CSF and sera from MS, AD, Parkinson’s
disease (PD), and control patients provided by The UK Multiple
Sclerosis Tissue Bank were also used.
We initially tested two CSF samples from MS patients (MD01
and MD02) for the presence of immunoglobulins using autolo-
gous serum from these patients (Figure 2). Following centrifu-
gation of 2 ml of CSF aliquots (800× g, 5 min), supernatants
were kept at −80°C until further analyses. Trichloroacetic acid
(TCA)/acetone precipitation protocol was used to precipitate pro-
teins from supernatants and total protein concentrations were
measured using the BCA Protein Assay (Pierce). We reasoned that
serum of patients with MS would contain specific IgG and/or IgM
antibodies that can discriminate against proteins (oligomers and
others) associated with the pathologic process. In that context,
20µl of 10 mg/ml total protein derived from CSF samples (pri-
mary progressive: CSF 1 and secondary progressive: CSF 2) from
MS patients were electrophoresed by Western blot then probed
with serum (serum 1 and serum 2) from the same patients. Anti-
IgG or anti-IgM HRP conjugated antibody (1 in 10,000) was used
as secondary detection antibody. Sera from both MS patients were
able to immunodetect an extra band (~95 kDa) in CSF from
the same patients (Figure 2). Of note, the secondary antibodies
were unable to bind to the 95 kDa band when sera were omit-
ted, confirming its disease specificity. Finally, the 95 kDa band was
recognized by both IgG and IgM antibody present in sera of MS
patients (Figure 2).
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FIGURE 2 | Presence of oligoclonal bands in CSF samples from MS
patients. CSF samples from MS (primary progressive: MD01 and
secondary progressive: MD02) were electrophoresed then probed with
autologous serum (1, 2, 3, and 4). Secondary anti-IgM (1 and 2) or anti-IgG
(3 and 4) HRP-conjugate was used for detection of the autologous sera.
Sera were omitted from lanes 5, 6, 7, and 8 to confirm their binding
specificity after addition of secondary anti-IgM (5 and 6) or anti-IgG (7 and 8)
HRP-conjugate.
Next, we set out to determine whether soluble oligomers would
be detected by anti-oligomer PRIOC mAbs in brains and CSF of
MS patients. Brain samples (MS074, MS076, MS079, and MS094)
to be electrophoresed were diluted 1:1 in 40 ml sample buffer and
boiled for 5 min in eppendorf tubes. The samples were spun for
5 s at 14,000 rpm in a microfuge before being loaded on the gel.
CSF samples were prepared as described above. We probed for
soluble oligomers with Western blot and we show for the first
time that our anti-oligomer mAbs were able to detect soluble
oligomers in human brain homogenates and CSF from MS patient
but not in control brain (Figure 3A). Furthermore, Western blot
analysis of human brain homogenates and CSF from MS patients
revealed that our mAbs were able to detect several bands rang-
ing between 90 and 200 kDa (Figure 3A), consistent with the
smeary appearance normally seen with similar antibodies used
by other researchers to immunodetect soluble oligomers. Control
brain isolated from a young patient who died from lung cancer
(Ct, CO41) did not display soluble oligomers-specific bands on
Western blot (Figure 3A); in contrast and as expected,Western blot
of brain and CSF isolated from a patient with Parkinson’s disease
(PD; PD020) led to detection of soluble oligomers (Figure 3A).
We then expanded our study to include 27 MS samples to con-
firm the presence of the soluble oligomers in brain and CSF and
validate the above data. We used our previously published Sand-
wich ELISA assay specifically developed to immunodetect soluble
oligomers (11). The assay relies on a two-site system that includes
an immunocapture PRIOC antibody with the ability to capture
the oligomers, followed by Immunodetection with biotinylated
PRIOC. All 15 brain homogenates derived from MS patients
(Table 1) displayed high levels of soluble oligomers by ELISA,
similar to levels seen in AD and PD patients but not in the cancer
patients (Figure 3B). Twelve CSF samples derived from the MS
patients (Table 1) also showed high OD values by ELISA albeit
these were a third to half the levels seen in the brain homogenates
(Figure 3B).
Proteinase K (PK)-sensitive oligomers are considered the toxic
species in protein-misfolding diseases (PMDs) and have been
demonstrated by many research groups (7). We wanted to con-
firm whether soluble oligomers immunodetected in MS displayed
resistance to PK and behaved in a prion-like fashion. Brain
homogenates from patients with MS (secondary progressive) and
PD were subjected to appropriate concentration of PK; as low
as 6.25µg/ml of PK led to complete digestion of the soluble
oligomers (Figure 4A), consistent with previous work with PD
and prion.
Finally, co-morbidities are a recognized feature following
autopsy of patients with PMDs; for instance, both Parkinson’s and
AD have been recognized in same patients. We therefore wanted
to assess whether brain homogenates derived from MS patients
displayed PK-resistant prions (Figure 4B) and we also checked
for the presence of Aβ and α-synuclein (data not shown). Brain
homogenates from patients with MS (Secondary progressive) did
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FIGURE 3 | (A) Detection of soluble oligomers in brain homogenate
and CSF of patients with multiple sclerosis. Brain homogenates and
CSF samples MS094; MS074; MS076; MS079) from MS patients were
probed with anti-oligomer mAbs. Several bands (90–200 kDa range)
consistent with the oligomeric profile recognized on Western blotting have
been detected. Positive control Parkinson’s disease (PD) brain homogenate
and CSF displayed similar pattern as opposed to the human control
(Ct, CO41) brain, which failed to show oligomer detection. (B) Brain
homogenates and/or CSF derived from MS, PD, AD, and lung cancer were
used to assess specific binding of PRIOC mAb to soluble oligomers in a
Sandwich ELISA assay. PRIOC was used to coat the ELISA plate in coating
buffer. Brain homogenate and/or CSF were added to the wells followed by
a biotinylated PRIOC mAb. Error bars represent the mean antibody level
derived from n=4 wells.
not display any presence of PK-resistant prions as assessed by anti-
prion antibody and also failed to demonstrate binding for Aβ and
α-synuclein.
Our study shows for the time that protein aggregates detected
by anti-oligomer specific antibodies are associated with MS. The
data generated so far does not allow to reach a substantive con-
clusion in relation to the involvement of these proteins aggre-
gates in MS pathogenesis. Protein aggregation associated with MS
has been described previously in a rodent model of MS (16).
Dasgupta and colleagues have demonstrated increased protein
aggregation in the spinal cord of mice with experimental autoim-
mune encephalomyelitis (EAE). In their study, they argue that
accumulation of misfolded proteins is caused by increased rate of
protein oxidation and reduced proteasome degradation, both seen
in MS (17) and EAE (18, 19).
In conclusion, for the first time, we demonstrate the presence of
soluble oligomers, normally associated with PMDs, in MS tissues
and CSF. Although the pathogenic relevance of these MS associated
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FIGURE 4 | (A) Proteinase K sensitive oligomers or prions in brain
homogenate of patients with multiple sclerosis. Brain homogenates from MS
patients (MS079) were probed with anti-oligomer mAbs. The bands
(90–200 kDa range) demonstrated with the anti-oligomer antibody in both MS
and the positive control Parkinson’s disease (PD) brain homogenates via
western blotting, were no longer seen following proteinase K digestion.
(B) Brain homogenates (MS074; MS076) from MS patients and the human
control (Ct; CO41) brain were probed with anti-PrP 3F4 mAb to immunodetect
the typical PrP bands. RML (PrPSc)-infected brain homogenate was used to
probe for the PK sensitivity and was shown to display the 27–30 kDa band.
soluble oligomers to disease process remains to be investigated,
this study sets the ground for further investigating this relation-
ship. This study proposes a novel alternative in understanding the
pathogenesis of MS.
AUTHOR CONTRIBUTIONS
Monique Antoinette David designed and performed the experi-
ments; Mourad Tayebi designed and managed experiments and
wrote the manuscript.
ACKNOWLEDGMENTS
We are grateful to The UK Multiple Sclerosis Tissue Bank for pro-
viding us with brain and CSF samples. This work was funded by
the George and Cynthia Mitchell Foundation. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
REFERENCES
1. Owens GP, Bennett JL, Lassmann H, O’Connor KC, Ritchie AM, Shearer A,
et al. Antibodies produced by clonally expanded plasma cells in multiple
sclerosis cerebrospinal fluid. Ann Neurol (2009) 65:639–49. doi:10.1002/ana.
21641
2. Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding
NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case
control study of 100 patients. J Neurol Neurosurg Psychiatry (2009) 80:292–6.
doi:10.1136/jnnp.2008.150896
3. Corcione A, Aloisi F, Serafini B, Capello E, Mancardi GL, Pistoia V, et al. B-cell
differentiation in the CNS of patients with multiple sclerosis. Autoimmun Rev
(2005) 4:549–54. doi:10.1016/j.autrev.2005.04.012
4. Muhammad K, Roll P, Einsele H, Dorner T, Tony HP. Delayed acquisition of
somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors
after rituximab treatment. Arthritis Rheum (2009) 60:2284–93. doi:10.1002/art.
24722
5. Baumgarth N. A two-phase model of B-cell activation. Immunol Rev (2000)
176:171–80. doi:10.1034/j.1600-065X.2000.00606.x
6. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu
Rev Immunol (1997) 15:235–70. doi:10.1146/annurev.immunol.15.1.235
Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology December 2014 | Volume 5 | Article 251 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
David and Tayebi Protein-misfolding and MS
7. Tayebi M, Bate C, Hawke S, Williams A. A role for B lymphocytes in anti-
infective prion therapies? Expert Rev Anti Infect Ther (2007) 5:631–8. doi:10.
1586/14787210.5.4.631
8. Selkoe DJ. Amyloid protein and Alzheimer’s disease. Sci Am (1991) 265:68–78.
doi:10.1038/scientificamerican1191-68
9. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid
precursor protein (APP) expression in multiple sclerosis lesions. Glia (1995)
15:141–51. doi:10.1002/glia.440150206
10. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid:
an update on methodology and clinical usefulness. J Neuroimmunol (2006)
180:17–28. doi:10.1016/j.jneuroim.2006.07.006
11. Tayebi M, Jones DR, Taylor WA, Stileman BF, Chapman C, Zhao D, et al. PrPSc-
specific antibodies with the ability to immunodetect prion oligomers. PLoS One
(2011) 6(5):e19998. doi:10.1371/journal.pone.0019998
12. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al.
Common structure of soluble amyloid oligomers implies common mechanism
of pathogenesis. Science (2003) 300:486–9. doi:10.1126/science.1079469
13. David MA, Jones DR, Tayebi M. Potential candidate camelid antibodies
for the treatment of protein-misfolding diseases. J Neuroimmunol (2014)
272(1–2):76–85. doi:10.1016/j.jneuroim.2014.05.001
14. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer
WF, et al. Intracerebroventricular amyloid-beta antibodies reduce cerebral amy-
loid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc
Natl Acad Sci USA (2009) 106(11):4501–6. doi:10.1073/pnas.0813404106
15. Biernat J, Mandelkow EM, Schröter C, Lichtenberg-Kraag B, Steiner B, Berling
B, et al. The switch of tau protein to an Alzheimer-like state includes the phos-
phorylation of two serine-proline motifs upstream of the microtubule binding
region. EMBO J (1992) 11(4):1593–7.
16. Dasgupta A, Zheng J, Perrone-Bizzozero NI, Bizzozero OA. Increased carbony-
lation, protein aggregation and apoptosis in the spinal cord of mice with exper-
imental autoimmune encephalomyelitis. ASN Neuro (2013) 5(2):AN20120088.
doi:10.1042/AN20120088
17. Zheng J, Bizzozero OA. Decreased activity of the 20S proteasome in the brain
white matter and gray matter of patients with multiple sclerosis. J Neurochem
(2011) 117:143–53. doi:10.1111/j.1471-4159.2011.07182.x
18. Zheng J, Bizzozero OA. Reduced proteasomal activity contributes to the
accumulation of carbonylated proteins in chronic experimental autoimmune
encephalomyelitis. J Neurochem (2010) 115:1556–67. doi:10.1111/j.1471-4159.
2010.07062.x
19. Zheng J, Dasgupta A, Bizzozero OA. Changes in 20S subunit composition are
largely responsible for altered proteasomal activities in experimental autoim-
mune encephalomyelitis. J Neurochem (2012) 121:486–94. doi:10.1111/j.1471-
4159.2012.07699.x
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 11 April 2014; accepted: 13 November 2014; published online: 02 December
2014.
Citation: David MA and Tayebi M (2014) Detection of protein aggregates in brain and
cerebrospinal fluid derived from multiple sclerosis patients. Front. Neurol. 5:251. doi:
10.3389/fneur.2014.00251
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the
journal Frontiers in Neurology.
Copyright © 2014 David and Tayebi. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org December 2014 | Volume 5 | Article 251 | 7
